Streptozotocin is accustomed by the U.S. Food and Drug Administration (FDA) for alleviative metastatic blight of the pancreatic islet cells. Since it carries a abundant accident of toxicity and rarely cures the cancer, its use is about bound to patients whose blight cannot be removed by surgery. In these patients, streptozotocin can abate the bump admeasurement and abate affection (especially hypoglycemia due to boundless insulin beard by insulinomas). A archetypal dosage is 500 mg/m2/day by intravenous injection, for 5 days, again every 4-6 weeks.
Due to its top toxicity to beta cells, in accurate researches, streptozotocin has aswell been continued acclimated for inducing insulitis and diabetes on beginning animals.